A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical Study

PHASE3Enrolling by invitationINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

September 27, 2023

Primary Completion Date

November 30, 2030

Study Completion Date

November 30, 2030

Conditions
Duchenne Muscular Dystrophy
Interventions
GENETIC

delandistrogene moxeparvovec

No study drug will be administered as part of this study. Eligible participants who received treatment with delandistrogene moxeparvovec during a previous clinical study will be included.

Trial Locations (37)

807

Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City

9000

Universitair Ziekenhuis Gent, Neuromuscular Reference Centre (NMRC), Ghent

10032

Columbia University Pediatric Neuromuscular Center, New York

14642

University of Rochester Medical Center, Rochester

16147

UOC Neurologia Pediatrica e Malattie Muscolari, Istituto G. Gaslini, Istituto Pediatrico di Ricovero e Cura a Carattere Scientifico, Genova

19104

Chiildren's Hospital of Philadelphia, Philadelphia

20122

UOC Neurologia, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan

21287

The Johns Hopkins Hospital, Rubenstein Child Health Bldg, Baltimore

23510

Children's Hospital of The King's Daughters, Norfolk

27705

Lenox Baker Children's Hospital (Duke University), Durham

32610

University of Florida Clinical Research Center, Gainesville

43205

Nationwide Children's Hospital, Columbus

45147

Universitätsklinikum Essen - Klinik für Kinderheilkunde I, Essen

46026

Hospital Universitario y Politecnico La fe. Neurology Department, Valencia

52242

University of Iowa ICTS Clinical Research Unit, Iowa City

53226

Children's Hospital Wisconsin, Milwaukee

60611

Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago

63110

Washington University School of Medicine, St Louis

72202

Arkansas Children's Hospital, Little Rock

75207

Children's Health Specialty Center, Dallas

84132

University of Utah Health, Salt Lake City

90095

UCLA Medical Center, Los Angeles

92123

Rady Children's Hospital, San Diego

94304

Lucile Packard Children's Hospital Stanford (LPCH), Palo Alto

95817

University of California, Davis, Sacramento

97239

Oregon Health and Science University, Portland

100225

National Taiwan University Hospital, Taipei

80045-7106

Children's Hospital of Colorado, Aurora

02115

Boston Children's Hospital, Boston

Unknown

Hong Kong Children's Hospital, Hong Kong

00168

UOC Neuropsichiatria Infantile, Area Salute del Bambino, Fondazione Policlinico Universitario A. Gemelli IRCCS, Universita Cattoclica del Sacro Cuore, Roma

650-0017

Kobe University Hospital, Kobe

187-8551

National Center of Neurology and Psychiatry, Kodaira

08950

Hospital Sant Joan de Deu, Esplugues de Llobregat

WC1N 1EJ

Great Ormond Street Hospital For Children NHS Foundation Trust, London

OX3 9DU

Oxford University Hospitals NHS Foundation Trust, Oxford

NE1 3BZ

Institute of Translational and Clinical Research, Newcastle upon Tyne

All Listed Sponsors
collaborator

Hoffmann-La Roche

INDUSTRY

lead

Sarepta Therapeutics, Inc.

INDUSTRY